NCT06173466CompletedPhase 4
Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone
Thoracic Paravertebral Block With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone for Postoperative Analgesia in Patients Undergoing Liver Resection
Source: ClinicalTrials.gov · Last updated 26 Jun 2025
Brief summary (registry, in English)
Liposomal bupivacaine is a novel long-acting local anesthetic approved by the FDA for postoperative analgesia because of its ability to significantly prolong the analgesic effect for up to 72 hours. Up to now, no study has demonstrated the effect of postoperative analgesia with liposomal bupivacaine by thoracic paravertebral block (TPVB). The aim of this study was to evaluate the efficacy of liposomal bupivacaine for pain management and recovery after liver resection. Methods: 96 patients were involved in this randomized, prospective, single-blind study. Patients with hepatocellular carcinoma who were undergoing liver resection were divided into two groups: liposome bupivacaine group (liposomal bupivacaine 133mg) and standard bupivacaine combined with dexamethasone group (standard bupivacaine 150mg and dexamethasone 5mg). Both groups were applied ultrasound guided TPVB. The primary outcome was the cumulative opioid consumptionfor 72 hours. Secodary outcomes included QoR-40 at 72 hours, pain visual analog scale (VAS) score area under the curve (AUC) from 6 hours to 3 months, sleep quality at 1 month and 3 months postoperatively. Adverse events and serious adverse events 3 months after TPVB were also recorded.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 96 (actual)
- First submitted
- 30 Nov 2023
- Start date
- 15 Dec 2023
- Primary completion date
- 28 Feb 2024
- Lead sponsor
- Zhejiang Cancer Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06173466
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 96
- From 15 Dec 2023 to the primary completion date, 28 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Anergic to medications used in this study;
- Patient receiving anticoagulants, opioids or have a history of narcotic abuse or alcohol abuse;
Other illness
- Patients with contraindications for local nerve block such as spinal anatomic structure abnormality or local infection of puncture area;
- Unable to complete postoperative pain score assessment or questionnaires or have mental disorders;
Other
- Patient have chronic pain;
- Pregnant;
- BMI ≥30 kg/m2;
- Patient involving in other studies.
Who the study is looking for
- 18-75 years old;
- American Society of Anesthesiologist physical status I-III;
- Child-Pugh score A-B;
- Non anergic to medication used in this study;
- Optional/scheduled for liver resection;
- Approved participation before study.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhejiang Cancer Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.